Patients with stroke have a 25x higher risk of cardiovascular complications within the first 30 days of the event compared to individuals without stroke. The mechanisms behind these complications are not well understood. Evidence suggests that inflammation plays a central role. With the present proof-of-concept prospective cohort study, the investigators aim to demonstrate that patients develop cardiac inflammation after stroke by performing positron emission tomography (PET) magnetic resonance imaging (MRI) of the heart within 15 days after stroke. As a secondary aim, the investigators will evaluate whether post-stroke cardiac inflammation persists at 3 months after stroke. The control group will be comprised of age- and sex-matched individuals without stroke.
Study Type
OBSERVATIONAL
Enrollment
1
Patients will undergo cardiac PET/MRI scanning at 30±5 days and at 90±5 days post-stroke.
Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 30±5 days and at 90±5 days post-stroke
NT-proBNP is useful both in the diagnosis and prognosis of heart failure and is considered to be a gold standard biomarker in heart failure. Measurement of NT-proBNP on patients' blood samples at 30±5 days and at 90±5 days post-stroke
Heart & Brain Lab, Western University
London, Ontario, Canada
Cardiac Inflammation Levels at 30±5 Days Post-Stroke measured by PET/MR Scanning
Cardiac inflammation as measure on PET/MR scanning.
Time frame: At 30 days±5 post stroke
Cardiac Inflammation Levels at 90±5 Days Post-Stroke measured by PET/MR Scanning
Cardiac inflammation as measure on PET/MR scanning.
Time frame: At 90±5 days compared to first 30 days±5 post-stroke
Change in B-Type Natriuretic Peptide (NT-proBNP) and HS-TnT levels between 30±5 days and 90±5 days post-stroke.
Change in levels of NT-proBNP and HS-TnT between 30±5 and 90±15 days post-stroke.
Time frame: At 90±5 days compared to first 30±5 days post stroke
Change in systemic inflammatory markers between 30±5 and 90±5 days post-stroke
Systemic inflammatory markers will be measured using a high-performance biomarker panel for the following 92 proteins (all of which will be informed in pg/mL): ADA; ARTN; AXIN1; NGF; CCL13; CCL19; CCL2; CCL20; CCL23; CCL25; CCL28; CCL3; CCL4; CCL7; CCL8; CXCL10; CXCL11; CXCL5; CXCL6; CXCL9; CDCP1; CASP8; CST5; DNER; CCL11; EIF4EBP1; FGF19; FGF21; FGF23; FGF5; FLT3LG; CX3CL1; GDNF; CXCL1; HGF; IFNG; IL1A; IL10; IL10RA; IL10RB; IL12B; IL13; IL15RA; IL17A; IL17C; IL18; IL18R1; IL2; IL2RB; IL20; IL20RA; IL22RA1; IL24; IL33; IL4; IL5; IL6; IL7; CXCL8; MMP1; KITLG; LIF; LIFR; LTA; CSF1; SIRT2; CD244;NTF3;NRTN;OSM;CD274;S100A12;TGFA;STAMBP;SLAMF1;MMP10;SULT1A1;CD6;CD5;CD8A;TSLP;TGFB1;TNF;TNFSF10;TNFSF11;TNFSF12;TNFSF14;TNFRSF11B;CD40;TNFRSF9;PLAU;VEGFA
Time frame: At 90±5 days compared to first 30±5 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.